We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Binding-Activated Fluorescent Biosensors Open Vast Possibilities for Medical Diagnostics

By LabMedica International staff writers
Posted on 09 Sep 2024

Biosensors are devices that utilize biological molecules to detect specific substances, holding significant potential for identifying disease biomarkers, monitoring biological processes, or detecting environmental toxins. More...

Among these, fluorescent biosensors are common; they involve a biomolecule that binds to a target attached to a probe molecule emitting fluorescent light. Traditional fluorescent biosensors often suffer from low contrast because their probes are always “on,”, requiring unbound biosensor molecules to be washed away for accurate signal detection. A significant advancement in this field is the development of high-contrast “binding-activated fluorescent biosensors” or nanosensors, which light up only upon binding to their specific targets. However, designing nanosensors that combine effective target-binding with an activated fluorescence switch within a compact molecular structure suitable for diverse samples and scalable, cost-effective production poses significant challenges.

Addressing these challenges, a collaborative research effort involving scientists from the Wyss Institute at Harvard University (Boston, MA, USA) has resulted in the development of a synthetic biology platform that simplifies the discovery, molecular evolution, and economical production of small, highly efficient nanosensors. These nanosensors can detect specific proteins, peptides, and small molecules, enhancing their fluorescence by up to 100 times in less than a second upon binding. Central to the platform is the use of novel fluorogenic amino acids (FgAAs) that are integrated into small protein sequences (binders) through an innovative method that allows for the in vitro expansion of the genetic code. This process facilitates high-throughput screening, validation, and directed evolution of protein binders into high-contrast nanosensors, accelerating development across various fields including basic research, environmental science, medical diagnostics, and enhanced therapeutics. The findings of the research have been published in Nature Communications.

“We have long worked on expanding the genetic code of cells to endow them with new capabilities to enable research, biotechnology, and medicine in different areas, and this study is a highly promising extension of this endeavor in vitro,” said Wyss Core Faculty member George Church, Ph.D., who led the study. “This novel synthetic biology platform solves many of the obstacles that stood in the way of upgrading proteins with new chemistries, as exemplified by more capable instant biosensors, and is poised to impact many biomedical areas.”

“This is an important step forward in our capabilities to quickly design low-cost fluorescent biosensors for real-time disease monitoring and with huge potential for diagnostics and precision medicine,” added co-corresponding author Marc Vendrell, Ph.D., a Professor at the University of Edinburgh.

Related Links:
Wyss Institute at Harvard University


New
Gold Member
Latex Test
SLE-Latex Test
Serological Pipet Controller
PIPETBOY GENIUS
New
Gold Member
Serological Pipets
INTEGRA Serological Pipets
New
Pan-Cancer Panel
TruSight Oncology 500
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
These images illustrate how precision oncology Organ Chips recapitulate individual patients’ responses to chemotherapy (Photo courtesy of Wyss Institute at Harvard University)

Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response

Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.